გამოქვეყნდა: ავტორი — კომენტარის დატოვება

JIFU® LIV™ Glutathione Supplement and Autism Claims

JIFU

Date: 25 November 2025

Status: Expert public-health opinion based on independently verifiable scientific and legal sources

1. Mandate and scope of this statement

The Public Health Institute of Georgia (PHIG) is an independent, non-commercial organization. Our mandate is to:

  • Protect the health of the population;
  • Promote evidence-based practice in health and nutrition;
  • Support Georgian regulators and consumers in making informed decisions about health products.

This statement examines the product LIV™, marketed under the JIFU® brand, and addresses recent social-media marketing in Georgia where LIV is presented, explicitly or implicitly, as a treatment for autism in children. It explains why PHIG considers such marketing unacceptable, scientifically unfounded, and incompatible with Georgian, EU, and US regulatory frameworks.

This document is not a legal ban and does not replace the authority of Georgian governmental bodies (National Food Agency, State Regulation Agency for Medical Activities, Competition and Consumer Agency, Georgian National Communications Commission, etc.). It is an independent expert risk assessment and policy position intended for:

  • Consumers and parents in Georgia;
  • Healthcare professionals;
  • Regulatory and oversight authorities;
  • JIFU distributors and affiliates active on the Georgian market.

2. JIFU, LIV™ and what the official materials claim

JIFU LLC is a US-based company (JIFU USA: Salt Lake City, Utah; JIFU Europe B.V.: Groningen, Netherlands) that promotes a combined “lifestyle membership” including travel, education and health products.[25] Under the “JIFU health” line, it markets several food supplements such as Gen3™, LIV™, glo™ and STM™.[2,7,18,25]

According to JIFU’s own product pages:

  • LIV™ is described as a “superfruit antioxidant blend” designed to “optimize your health”, “defend your cells”, “support your immune system” and “promote long-term vitality”, containing 10 super fruits plus resveratrol and glutathione in a mixed-berry flavor.[0,3,4,10,11,12,14]
  • LIV is sold as a food supplement at prices around $100–$130 per box, via JIFU’s global webshop and country-specific portals (EU, USA, etc.).[3,4,6,11,15,21,28]
  • For other JIFU health products (e.g. STM), the company clearly states that they are food supplements, not substitutes for a varied diet, and that “these statements have not been evaluated by the Food and Drug Administration (FDA).”[13,25]

In other words, at corporate level JIFU presents LIV as a general antioxidant / wellness supplement, not as a medicine or autism treatment.

3. Glutathione and autism: what science actually says

LIV’s main selling point – in both JIFU’s own materials and in Georgian promotional content – is its content of glutathione, often called the “master antioxidant”. Scientifically:

  • Glutathione (GSH) is a tripeptide (glutamate, cysteine, glycine) with a central role in cellular redox balance, detoxification and antioxidant defense.
  • Systematic reviews and meta-analyses show that children with autism spectrum disorder (ASD) often have altered oxidative stress markers and lower levels of reduced glutathione, along with higher oxidized glutathione, compared with controls.[3,7,11,15,19]

However, very important distinctions must be made:

  • These studies show an association (altered glutathione metabolism in ASD), not proof that taking oral glutathione or an antioxidant drink such as LIV will treat or cure autism.[3,7,11,15]
  • Clinical guidelines for autism (e.g. American Academy of Pediatrics (AAP), CDC, professional societies) emphasise early diagnosis, behavioural and educational interventions, speech and occupational therapy, and family support as the cornerstones of care – not dietary supplements as primary treatment.[2,6,10,14,18]
  • AAP and other expert bodies explicitly warn that many “biomedical” or supplement-based interventions for autism lack adequate evidence, and some may be harmful or may delay effective, evidence-based care.[2,6,10,14]

There is currently no regulatory approval in the US, EU or Georgia for any glutathione-based product as a registered medicine for autism. Glutathione and antioxidant strategies remain an area of research, not an established, authorised treatment for ASD.

4. Georgian social-media marketing linking LIV™ to autism

PHIG has reviewed publicly accessible Georgian-language social-media content shared via Facebook and other platforms, provided by concerned citizens, including:

  • Facebook Reels (links supplied by the complainant) where a person identified as a JIFU/LIV representative in Georgia appears in short interviews with parents of autistic children. In these videos, the representative invites parents to describe their children’s autism and then to talk about perceived improvements after using LIV; the framing clearly suggests that LIV is responsible for improvements in autism-related symptoms.
  • A long Georgian post widely circulated under hashtags #ლივი #LIV, which presents glutathione as a key ingredient of LIV and then claims, in sweeping terms, that disordered glutathione metabolism is central to “diabetes, cancer, all chronic diseases, infertility, autoimmune diseases, all skin diseases, all neurological conditions including Parkinson’s, depression, schizophrenia, migraine, stroke, thyroid disorders – and autism and childhood neurodevelopmental disorders”. Autism is explicitly listed as a condition linked to “glutathione cycle dysfunction” and the text strongly implies that correcting glutathione via products like LIV is essential for recovery.

PHIG emphasises that:

  • These materials, as presented to the Georgian public, go far beyond JIFU’s own official marketing (which focuses on general antioxidant and wellness claims).
  • They explicitly or implicitly frame LIV as a treatment for autism and many other serious diseases, relying mainly on anecdotal parental testimonials and broad physiological speculation about glutathione.
  • Such messaging targets a particularly vulnerable group – parents of autistic children – who may be desperate for help and therefore especially susceptible to misleading claims.

Even if JIFU corporate has not authorised these specific autism-related statements, the content is clearly associated with the LIV brand and appears to be disseminated by people acting as JIFU distributors or promoters in Georgia. From a public-health and consumer-protection standpoint, this is unacceptable.

5. Regulatory frameworks: Georgia, EU and US

5.1. Georgia

In Georgia:

  • The Law of Georgia on Advertising prohibits improper, unfair, unreliable and clearly false advertising, and applies to all media.[19]
  • Legal analyses of advertising of pharmaceutical products and biologically active additives underscore that supplements may not be promoted as if they cured or treated specific diseases, and that health claims must be truthful and evidence-based.[22]

Marketing a food supplement as an autism treatment, or suggesting that it can substitute for medical or behavioural therapy, is incompatible with these principles.

5.2. European Union

In the EU:

  • Regulation (EC) No 1924/2006 on nutrition and health claims for foods allows only authorised claims and prohibits disease-treatment or disease-prevention claims for ordinary food supplements; such claims are reserved for medicinal products authorised under Directive 2001/83/EC.
  • The Court of Justice of the EU has clarified that food for special medical purposes (FSMP) cannot be used as a bypass to make medicinal-type claims without meeting strict disease-related nutritional criteria.[10,11]

Positioning an antioxidant drink as a treatment for autism would be considered a medicinal claim in EU law, requiring a marketing authorisation as a medicinal product and a robust clinical evidence base – which LIV does not have.

5.3. United States

In the US:

  • Under DSHEA, dietary supplements are regulated as foods; they cannot lawfully be marketed as treatments for diseases (e.g. autism) without being approved as drugs.[5–7,23,26]
  • The FDA has issued warning letters to companies promoting glutathione products as necessary to treat conditions including autism and ADHD, classifying such products as unapproved new drugs when disease treatment claims are made.[0]
  • The Federal Trade Commission (FTC) has taken enforcement actions against companies that claimed supplements could treat childhood speech disorders associated with autism, securing settlements and refunds for consumers and explicitly warning against deceptive marketing to parents of autistic children.[1,5,9,17]
  • The FTC has a long-standing programme to combat fraudulent and deceptive advertising of supplements, “especially when it comes to products marketed to or for children.”[9]

These precedents show that supplement-based autism treatment claims are not tolerated in US enforcement practice and are likely to be considered illegal.

6. Why autism-treatment marketing for LIV™ is harmful

Beyond law and regulation, PHIG stresses the concrete public-health risks:

  • Delaying effective care: Parents who believe a supplement “treats autism” may delay or reduce engagement with evidence-based behavioural, educational and communication interventions, which are time-sensitive and critical for long-term outcomes.[2,6,10,14,18]
  • Financial exploitation: LIV is an expensive product. Encouraging families to purchase it regularly for autism, without solid evidence, risks significant financial strain.
  • False hope and psychological harm: Presenting autism as something that can be “cleaned” or “reversed” by an antioxidant drink promotes unrealistic expectations and can lead to guilt or blame if expected improvements do not occur.
  • Safety concerns: High-dose supplementation in children can carry risks (e.g. excessive antioxidant use, interactions with medications, exceeding tolerable upper intake levels), especially if used long term without medical supervision.[7,9,13–15]

For all these reasons, PHIG considers any autism-treatment messaging around LIV to be dangerous and unethical.

7. PHIG’s official position on JIFU LIV™ and autism claims in Georgia

7.1. Non-recommendation for autism or other diseases

As of 25 November 2025, PHIG adopts the following position:

PHIG does not recommend the use of LIV™ or any other JIFU® supplement as a treatment for autism or any other medical condition in Georgia.

More specifically:

  • LIV may be considered, at most, a general antioxidant food supplement. There is no high-quality clinical evidence that LIV treats, cures or significantly improves autism spectrum disorder, nor has any major regulator authorised it for this purpose.
  • The use of LIV as a “detox” or “glutathione fixer” for autism – as suggested in some Georgian social-media content – is scientifically unproven and inconsistent with international autism treatment guidelines.[2,3,6,7,10,11,14,18,19]
  • PHIG strongly opposes any messaging that suggests LIV can replace or reduce the need for behavioural, educational and medical interventions in autism.

7.2. Position on Georgian social-media marketing and testimonials

Regarding the Georgian-language videos and posts that present LIV as an autism treatment:

  • PHIG considers it unacceptable and unethical for any distributor or representative associated with JIFU to solicit testimonials from parents of autistic children in a way that implies causality between LIV use and improvements in autism. Such practices risk being deceptive advertising, especially given the vulnerability of the target audience.
  • PHIG calls on JIFU LLC and its European and Georgian partners to immediately review and remove any autism-related treatment claims made in connection with LIV, and to issue clear internal guidance to their affiliates that such claims are prohibited.

7.3. Guidance for healthcare professionals and parents

PHIG recommends that healthcare professionals in Georgia:

  • Firmly advise parents that LIV is not a recognised treatment for autism and that no supplement should replace evidence-based interventions.
  • Discuss the current state of evidence on oxidative stress and autism in neutral, scientific terms, making clear that research on glutathione does not translate into approval of any specific glutathione-containing drink as a therapy.[3,7,11,15,19]
  • Report any suspected adverse effects or misleading marketing practices related to LIV to the relevant authorities.

PHIG advises parents:

  • To rely on qualified medical and psychological professionals for autism diagnosis and management.
  • To be very cautious about online testimonials and marketing claiming that any supplement, including LIV, can treat or cure autism.
  • To use PHIG-affiliated platforms (SheniEkimi.ge, SheniAmbebi.ge, Supplement.ge) for independent, evidence-based information in Georgian.

8. Recommendations to Georgian regulators

8.1. National Food Agency and health regulators

  • Review the registration and labelling status of LIV and other JIFU supplements in Georgia, ensuring they are correctly classified as food supplements and that composition and safety data are available.
  • Request that any distributor making disease-related claims provide a full dossier; if such claims are made, regulators should consider whether the products are effectively being marketed as unregistered medicinal products.

8.2. Competition and Consumer Agency

  • Assess whether social-media promotion of LIV as an autism treatment violates the Law of Georgia on Advertising (misleading, unfair or clearly false advertising).[19,22]
  • Issue guidance or take enforcement actions as needed, especially where vulnerable populations (children with autism and their families) are targeted.

8.3. Georgian National Communications Commission (GNCC)

  • Monitor broadcast and online content for covert or surreptitious advertising of LIV and similar products in health-related programmes, consistent with existing standards on hidden advertising.[20,21]
  • Require clear labelling of any content involving LIV where there is a commercial interest, and prevent presentation of promotional material as neutral medical advice.

9. Legal robustness of PHIG’s position

This position is grounded in:

  • JIFU’s own official materials, which define LIV as an antioxidant food supplement containing glutathione and superfruits for general wellness, not as a medicine for autism.[0,2–4,7,10–12,14,15,21,25,28]
  • Scientific literature demonstrating altered glutathione and oxidative stress markers in autism, but not establishing glutathione-containing supplements as approved treatments.[3,7,11,15,19]
  • Authoritative autism guidelines and public-health guidance from AAP, CDC and others, which emphasise behavioural and educational interventions, not supplements, as core treatment strategies.[2,6,10,14,18]
  • Regulatory and enforcement precedents from FDA and FTC, including warning letters and enforcement actions against companies claiming that glutathione or other supplements can treat autism or related conditions.[0,1,5,9,12,17,23]
  • Georgian and EU legal frameworks on food supplements and advertising, which restrict disease-treatment claims for non-medicinal products.[10,11,19,22,25]

PHIG does not allege that LIV is intrinsically unsafe when used as a general antioxidant supplement by healthy adults within normal dosing. Our concern is the combination of:

  • scientifically unsupported autism-treatment claims in Georgian social media;
  • marketing directed at a vulnerable group (families of autistic children);
  • the risk that such marketing will delay evidence-based care and mislead parents.

On this basis, and in line with the precautionary principle applied to vulnerable populations and high-risk claims, PHIG concludes that:

Any presentation of JIFU® LIV™ as a treatment for autism is scientifically unfounded, ethically unacceptable, and incompatible with Georgian, EU and US regulatory standards. Until robust, independently verified evidence and appropriate medicinal authorisations exist – which is not the case today – LIV should not be promoted or used as a therapy for autism in Georgia.

This statement is issued in good faith as an expert public-health opinion, based on sources that can be independently verified.

Sources

  1. JIFU. LIV – Optimize Your Health [Internet]. JIFU; c2024 [cited 2025 Nov 25]. Available from: https://jifu.com/liv/
  2. JIFU. Products – JIFU health [Internet]. JIFU; c2024 [cited 2025 Nov 25]. Available from: https://jifu.com/products/
  3. Frustaci A, Neri M, Cesario A, et al. Oxidative stress-related biomarkers in autism: systematic review and meta-analyses. Free Radic Biol Med. 2012;52(10):2128-41. Available from: https://pubmed.ncbi.nlm.nih.gov/22542447/
  4. JIFU. LIV Superfruit Antioxidant Blend – EU product page [Internet]. JIFU Shop; c2024 [cited 2025 Nov 25]. Available from: https://shop.jifu.com/en/gb/product/liv-gel-2-eu
  5. US Food and Drug Administration. Dietary Supplements [Internet]. Silver Spring (MD): FDA; 2024 Oct 1 [cited 2025 Nov 25]. Available from: https://www.fda.gov/food/dietary-supplements
  6. US Food and Drug Administration. Questions and Answers on Dietary Supplements [Internet]. Silver Spring (MD): FDA; 2024 Feb 21 [cited 2025 Nov 25]. Available from: https://www.fda.gov/food/…/questions-and-answers-dietary-supplements
  7. Pew Charitable Trusts. Dietary Supplements: What Are They and How Are They Regulated? [Internet]. 2017 Oct [cited 2025 Nov 25]. Available from: https://www.pewtrusts.org/…/hcp_dietary_supplements_what_are_they_and_how_are_they_regulated_final.pdf
  8. Chen L, Shi X, Yan Z, et al. Oxidative stress marker aberrations in children with autism spectrum disorder: A systematic review and meta-analysis. Transl Psychiatry. 2021;11:430. Available from: https://www.nature.com/articles/s41398-020-01135-3
  9. Hwang ES, Song SB. Possible adverse effects of high-dose nicotinamide: mechanisms and safety assessment. Biomolecules. 2020;10(5):687. Available from: https://www.mdpi.com/2218-273X/10/5/687
  10. Hyman SL, Levy SE, Myers SM; Council on Children with Disabilities, Section on Developmental and Behavioral Pediatrics. Identification, evaluation, and management of children with autism spectrum disorder. Pediatrics. 2020;145(1):e20193447. Available from: https://publications.aap.org/pediatrics/article/145/1/e20193447/36917
  11. Ghanizadeh A, Moghimi-Sarani E. Glutathione-related factors and oxidative stress in autism, a review. CNS Neurol Disord Drug Targets. 2013;12(6): 1-7. Available from: https://pubmed.ncbi.nlm.nih.gov/22708999/
  12. JIFU. LIV Superfruit Antioxidant Blend – USA product listing [Internet]. JIFU Shop; c2024 [cited 2025 Nov 25]. Available from: https://shop.jifu.com/…/category_all_products
  13. JIFU. STM – The future of cellular health [Internet]. JIFU; c2024 [cited 2025 Nov 25]. Available from: https://jifu.com/stm/
  14. Kuźniar-Pałka A, et al. The role of oxidative stress in autism spectrum disorder: a narrative review. Biomedicines. 2025;13(2):388. Available from: https://www.mdpi.com/2227-9059/13/2/388
  15. Healthy Lifestyle Shop. LIV Superfruit Antioxidant Blend – JIFU [Internet]. 2024 [cited 2025 Nov 25]. Available from: https://healthy-lifestyle-shop.com/product/liv-superfruit-antioxidant-blend/
  16. US FDA. Warning Letter to John Gray’s Mars Venus, LLC [Internet]. 2019 Feb 5 [cited 2025 Nov 25]. Available from: https://www.fda.gov/…/john-grays-mars-venus-llc-564498-02052019
  17. FTC. Company That Touted Products’ Ability to Treat Children’s Speech Disorders Settles FTC Charges [Internet]. 2015 Jan 9 [cited 2025 Nov 25]. Available from: https://www.ftc.gov/…/company-touted-products-ability-treat-childrens-speech-disorders
  18. FTC. FTC Sends Refund Checks Totaling Almost $175,000 to Consumers Who Bought Deceptively Marketed Supplements to Treat Childhood Speech Disorders [Internet]. 2015 Aug 24 [cited 2025 Nov 25]. Available from: https://www.ftc.gov/…/ftc-sends-refund-checks-totaling-almost-175000
  19. Court of Justice of the European Union. Judgment of 27 October 2022, Case C-418/21 (FSMP) [Internet]. Luxembourg: CJEU; 2022 [cited 2025 Nov 25]. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:62021CJ0418
  20. Walder Wyss Ltd. Food for Special Medical Purposes (FSMP): New Specific CJEU Requirements [Internet]. 2023 Jan 13 [cited 2025 Nov 25]. Available from: https://www.walderwyss.com/…/fsmp-new-specific-cjeu-requirements
  21. CDC. Treatment and Intervention for Autism Spectrum Disorder [Internet]. Atlanta (GA): CDC; 2024 May 16 [cited 2025 Nov 25]. Available from: https://www.cdc.gov/autism/treatment/index.html
  22. AAP. Autism Spectrum Disorder – AAP Recommendations [Internet]. Itasca (IL): American Academy of Pediatrics; 2023 [cited 2025 Nov 25]. Available from: https://www.aap.org/en/patient-care/autism/
  23. Parliament of Georgia. Law of Georgia on Advertising [Internet]. 1998 Feb 18 (as amended) [cited 2025 Nov 25]. Available from: https://assets.tobaccocontrollaws.org/…/Georgia-Law-on-Advertising.pdf
  24. Media Development Foundation. Surreptitious Advertising [Internet]. Tbilisi (GE); 2011 Oct 12 [cited 2025 Nov 25]. Available from: https://mdfgeorgia.ge/uploads//Surreptitious_Advertising-ENG.pdf
  25. Grata International. Advertising and Promotion of Pharmaceutical Products and Biologically Active Additives in Georgia [Internet]. 2024 Apr 29 [cited 2025 Nov 25]. Available from: https://gratanet.com/publications/advertising-and-promotion-of-pharmaceutical-products-and-biologically-active-additives-in-georgia
  26. JIFU. STM OMG – The Next Generation Omega-3 [Internet]. JIFU; c2024 [cited 2025 Nov 25]. Available from: https://jifu.com/stm-omg/

0 0 ხმის მიცემა
Article Rating
guest
0 კომენტარები
Oldest
Newest Most Voted
Inline Feedbacks
ყველა კომენტარის ნახვა